Hope for BET inhibition in patients with leukaemia or lymphoma

Affiliations

¹ Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute and Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL 33612, USA. Electronic address: Mohamed.Kharfan-Dabaja@Moffitt.org.

Comment

Mohamed A Kharfan-Dabaja. Lancet Haematol. 2016 Apr.

. 2016 Apr;3(4):e157-8.

doi: 10.1016/S2352-3026(15)00253-7. Epub 2016 Mar 18.

¹ Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute and Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL 33612, USA. Electronic address: Mohamed.Kharfan-Dabaja@Moffitt.org.

No abstract available

Comment on

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H. Berthon C, et al. Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18. Lancet Haematol. 2016. PMID: 27063977 Clinical Trial.
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. Amorim S, et al. Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18. Lancet Haematol. 2016. PMID: 27063978 Clinical Trial.